How will you decide who to offer ramucirumab + pembro after progression on chemoimmunotherapy?
Are there specific patient factors for which you would more preferentially use this regimen?
Answer from: Medical Oncologist at Academic Institution
In S1800A, overall survival benefit was relatively consistent across subgroups including TMB levels and PD-L1 strata. I would take into account the patient’s prior response to ICI (extent and duration) and the side effects from the ICI therapy. For instance, I would favor chemotherapy for thos...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
As of today, I would offer ram/pembro to patients who were previously treated with IO, were not primary progressors, and who do not have imminent organ failure, pain, or other requirements for a rapid response. Notably, response rates to investigators-choice SOC (doce/ram, doce, gem, or pemetrexed) ...
Answer from: Medical Oncologist at Community Practice
A more pronounced benefit was seen with ramucirumab and pembrolizumab in patients with SCC or mixed histology NSCLC where options for therapy may be more limited. Overall, all subgroups did derive benefit.
Answer from: Medical Oncologist at Community Practice
Currently, ramucirumab + pembrolizumab is not an approved regimen by the FDA and is based on positive Phase II data from SWOG S1800A. Though the results were quite promising, it would be best to enroll patients in the confirmatory study SWOG S2302 (Pragmatica-Lung). In principle, at minimum, the par...